An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.
Xkin Suture Device Acts as Effective Wound Closure Method, Improves Scar Outcomes
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
Managing Food Allergies with Dupilumab in Pediatric Dermatology